Request Consultation
Biomarkers are measurable indicators in the body that show a response to an irreversible, progressive brain disorder called Alzheimer’s disease, emphasizing fundamental brain pathology.
Classifying Alzheimer’s Biomarkers into Prominent Categories:
Top-Rated Leaders of the Alzheimer’s Disease Biomarkers & Their Offerings, Include:
| In-Vitro Diagnostics (IVD) & Global MedTech | |
| Roche Diagnostics | A major company involved in tailored medicine, known for its automated immunoassays & highly sensitive blood-based biomarker tests that determine amyloid-beta & tau proteins. |
| Siemens Healthineers | This is a key player in integrating cutting-edge PET neuroimaging tracers with blood-based biomarker analytics. |
| Abbott Laboratories | Its offering covers the highly sensitive Alinity i platform to explore AD biomarkers in blood & CSF. |
| Fujirebio | It has been innovating neurodegeneration diagnostics for over two decades, employing CSF assays & automated Lumipulse testing solutions. |
| Labcorp & Quest Diagnostics | These are significant reference laboratories unveiling commercial blood tests & testing services directly to healthcare providers |
| Specialty & Blood Biomarker Innovators | |
| Quanterix | A firm offers its ultrasensitive Simoa technology, which enables the detection of low-abundance neurodegenerative biomarkers in standard blood draws. |
| C2N Diagnostics | This leader raises efforts in blood-based tests, such as PrecivityAD & also assists in estimating cognitive decline & monitoring trial datasets. |
| ADx NeuroSciences | This player specializes in the development of state-of-the-art assays & antibodies to track Alzheimer’s disease expansion. |
| ALZpath | Another company highly emphasizes diagnostic tools with a specialized concentration on p-tau217 testing, a key blood biomarker for AD |
| Pharmaceutical & Contract Research Organizations (CROs) | |
| Eli Lilly & Company | A global company plays a vital role in both biomarker development & treatments, using substantial investments in clinical trials. |
| Biogen | This firm widely facilitates both therapeutic drugs & the correlative neurological biomarkers to monitor disease-modifying treatment effectiveness. |
| IXICO | This is an AI-driven neuroimaging contract research organization (iCRO) that offers biomarker analytics to promote clinical trials for Alzheimer's & other neurological diseases. |
Growth Factors of the Latest Biomarkers in Alzheimer’s Disease
Primarily, an excessive production or low clearance of amyloid precursor protein fragments results in the development of soluble oligomers & insoluble plaques in the brain. Hyperphosphorylated tau proteins, which form intracellular neurofibrillary tangles that destroy the neuron's transport system, are also a main driver of Alzheimer’s disease biomarkers.
Besides this, continuous breakthroughs in clinical studies, including targeted treatments, are relied on to find eligible patients for these studies, which measure whether the drug hits its biological target, & ensure disease progression, if something has been altered. However, various biomarker tests, like cerebrospinal fluid analysis or specialized blood tests, provide physicians with objective data on disease staging, allowing families & patients to make informed options & long-term care strategies.
Latest Launches of the Biomarkers Used in Alzheimer’s Disease Prevalences
- In March 2026, Siemens Healthineers introduced the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) & Atellica IM Brain Derived Tau (BDTau) assays for Alzheimer's and neurological disease.
- In January 2026, Mahajan Imaging & Labs explored its Alzheimer’s diagnostic capabilities with the rollout of an AI-integrated blood biomarker test, led by a structured PET & MRI imaging pathway.
- In January 2026, Alamar Biosciences, Inc. launched its Research Use Only (RUO) NULISAqpcr AD 5-plex Assay to bolster blood-based biomarker detection in Alzheimer's Disease research.
Prospective Immersive Research Pipelines in the Alzheimer’s Disease Biomarkers
One of the crucial biomarkers, Microtubule-Binding Region (MTBR)-tau243, will have a higher capability in tracking the spread of tau tangles across the brain, supporting researchers in assessing disease-modifying therapies. Also, researchers are increasingly stepping towards an evolution of point-of-care extracellular vesicle (EV)-derived proteomic signatures, which segregate brain-derived EVs directly from blood.
In the case of modern imaging approaches, leaders will have a greater opportunity to execute platforms, including the petBrain deep learning pipeline, allowing automated, end-to-end processing of amyloid-PET, tau-PET, & structural MRI scans, organizing imaging outputs perfectly with clinical trial standards.
This era and the coming decade are known for massive breakthroughs in digital & multi-modal biomarkers, which will foster AI-powered tools unified with blood proteomics, genetic risk factors & age-related data for early detection of cognitive decline.
Specifically, the Alzheimer’s Drug Discovery Foundation (ADDF) will offer funds for innovative peripheral biofluid, digital, & ocular biomarker programs, with applications reviewed continuously.
Approximate Cases of AD Across the World in the Future & Importance of Advanced Biomarkers
According to the Fisher Center for Alzheimer’s Research Foundation’s report, there will rise in AD cases of nearly greater than 83 million by 2030, 116 million by 2040, & 152 million by 2050. Firstly, biomarkers will support doctors in the detection of the accumulation of amyloid-beta plaques & abnormal tau proteins that develop in the brain up to 15 to 20 years before the occurrence of symptoms of cognitive decline. In the future, these biomarkers will expedite the drug development process by enabling researchers for rapid confirmation of hitting of a therapeutic drug at its target in the brain & also spurring shorten, more accurate clinical trials with rapid drug approvals.
Conclusion
The worldwide surging need for non-invasive, scalable population screening, earlier treatment, & rigorous monitoring of disease-modifying therapies, fueling the demand & adoption of novel biomarkers in AD. To broaden the applications of these biomarkers, leaders are empowering the development of capillary blood sampling via fingerprick tests, which offer self-administered, decentralized alternatives that correspond well with venous blood. Nowadays, ongoing regulatory changes, like the Alzheimer's Association's revised criteria, are spurring higher use of core fluid biomarkers for early, biological categorization.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
